– Nijmegen (The Netherlands) – MercachemSyncom today announced that it will change its name and operate under the registered trade name of Symeres. The new name reflects the strategic evolution of the company, with the growth of integrated drug discovery and development services,…
– Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis Amsterdam, The Netherlands - Calypso Biotech, a company developing Interleukin-15-targeted biologics, today…
– IRVINE, Calif. — (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230…
– Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study Target enrolment of up to 1,600 SA-AKI patients at ICUs in Europe, United Kingdom and North America Utrecht, The Netherlands – AM-Pharma…
– Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, today announced that it has acquired Admescope Ltd., a provider of ADME-Tox services, based in Oulu (Finland) and Södertälje…
– San Jose (CA, US) – Eargo, Inc. (“Eargo”), a medical device company dedicated to improving the quality of life of people with hearing loss, announced today the pricing of its initial public offering of 7,851,852 shares of its common stock at a public offering price of $18.00 per share.…
– NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, SOUTH AFRICA, CANADA, JAPAN Utrecht (The Netherlands) – Gilde Healthcare company Nyxoah (the “Company”) a health-technology company focused…
– Utrecht (The Netherlands) and Philadelphia – Gilde Healthcare company Lava Therapeutics announced the closing of an oversubscribed $83 million (€71 million) Series C financing to fund the advancement of its pipeline and platform. The financing was co-led by new investors Novo Ventures…
– Mont-Saint-Guibert (Belgium) and Utrecht (The Netherlands) – Nyxoah S.A. (“Nyxoah” or the “Company”) a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, today announces its…
– Cambridge (UK) and Indianapolis (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures,…
– Cambridge (UK) and Indianapolis (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures,…
– Boston (Massachusetts, US) and Utrecht (The Netherlands) – Lumeon, the leader in care pathway orchestration, today announced that it has closed $30M in Series D funding led by new investors Optum Ventures and Endeavour Vision, with participation from current investors Gilde Healthcare,…
– Utrecht (The Netherlands) and Amsterdam (The Netherlands) – LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug development. By quantifying binding strength between immune and cancer cells using the unique z-Movi®…
– Utrecht (The Netherlands) and Boston (Massachusetts, US) – CVRx, Inc., a private medical device company commercialising a novel technology that treats patients suffering from chronic heart failure ("HF") and resistant hypertension, announced today that it raised $50 million to close…
– MINNEAPOLIS (US) – CVRx, Inc., a private medical device company, announced today that its BeAT-HF phase III randomized clinical trial results were published in the Journal of the American College of Cardiology (“JACC”). Results from the trial were used to obtain Premarket Approval…
– CAMBRIDGE (UK), INDIANAPOLIS (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or…
– IRVINE, CALIFORNIA – Inari Medical Inc. today announced the closing of its initial public offering on NASDAQ. Inari is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. The gross proceeds…
– Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Dutch biopharmaceutical start-up Lava Therapeutics B.V., today announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson,…
– Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that is commercializing novel implantable rechargeable sacral neuromodulation devices (r-SNM Systems) for the treatment of bladder and bowel…
– Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress,…
– New Hampshire (United States) – Vapotherm, Inc. (NYSE: VAPO), the Gilde Healthcare company focused on the commercialization of its proprietary Hi-VNI Technology products that are used to treat patients suffering from respiratory distress, today announced an update on their business…
– Cambridge (United Kingdom) and Indianapolis (United States) – Acacia Pharma (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery,…
– Cambridge (United Kingdom) and Indianapolis (United States) – Gilde Healthcare company Acacia Pharma (EURONEXT: ACPH), a hospital pharmaceutical company focused on therapeutic solutions improving the care of patients undergoing significant treatments such as surgery, other invasive…
– Data Provide Preliminary Evidence of Efficacy of the Investigational Peregrine System Kit SAN JOSE, Calif. — Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced that positive six-month results from the Peregrine Post-Market…
– First patient dosed in phase 3 trial of SNF472 for the treatment of calcific uremic arteriolopathy (CUA) or calciphylaxis Palma, Spain and San Diego, USA – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced…
– Irvine, CA (United States) – Gilde Healthcare portfolio company Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of bladder…
– Cambridge (United Kingdom) and Indianapolis (United States) – Gilde Healthcare portfolio company Acacia Pharma Group plc (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, has been awarded BEL Small Company…
– Acacia Pharma has in-licensed exclusive US rights to ultra-short-acting sedative, ByFavo™ (remimazolam) from Cosmo adding to its portfolio of near-market products Cosmo will make a €10 million equity investment in Acacia Pharma and provide a new €35 million loan facility to support…
– Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, has announced that it has acquired Alcami’s European cGMP CMC drug substance development site, based in Weert, the Netherlands. The…
– Utrecht (the Netherlands) and Philadelphia (United States) – Gilde Healthcare company Lava Therapeutics (“LAVA”) announced that James P. Allison, Ph.D., a 2018 Nobel Prize recipient in Physiology or Medicine for his discovery of cancer therapy by inhibition of negative immune regulation,…